Newsroom

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced new results from the Phase 1b/2 EPCORE® NHL-2 trial Arm 10 (NCT04663347), evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, in combination with rituximab, ifosfamide, carboplatin, and etoposide (R-ICE) in adult patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) who are eligible for autologous stem cell transplantation (ASCT). Results demonstrated an o...

TOKYO--(BUSINESS WIRE)--ZAIKO will begin ticket sales on Sunday, June 15, 2025, at 6:00 PM JST for “BACK TO THE MEMORIES PART5,” starring FANTASTIC 6 -- a special unit of six members from LDH JAPAN’s FANTASTICS from EXILE TRIBE: Natsuki Sawamoto, Reiya Seguchi, Natsuki Hori, Keito Kimura, Yusei Yagi, and Sota Nakajima. [Event Details] BACK TO THE MEMORIES PART5 - Osaka Performance Start Times: Matinee: Saturday, June 21 at 12:00 PM Evening Show: Saturday, June 21 at 5:00 PM Ticket Purchase URL:...

東京--(BUSINESS WIRE)--(美國商業資訊)-- ZAIKO 將於 2025 年 6 月 15 日（星期日）日本時間下午 6 點，開始販售《BACK TO THE MEMORIES PART5》的門票。本次演出由 LDH JAPAN 所屬 FANTASTICS from EXILE TRIBE 中的 6 位成員組成的特別單元「FANTASTIC 6」主演，成員包括：澤本夏輝、瀬口黎弥、堀夏喜、木村慧人、八木勇征、中島颯太。 【活動資訊】 BACK TO THE MEMORIES PART5 – 大阪公演 演出時間： 日場：2025 年 6 月 21 日（星期六）中午 12:00 晚場：2025 年 6 月 21 日（星期六）下午 5:00 門票購買網址：https://fantastage-borderless.zaiko.io/?atprs ※門票可於大多數國家和地區購買及觀看，部分地區除外。 ※本次直播僅限海外觀眾觀看。...

VENLO, Netherlands & WILMINGTON, Del.--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) and Incyte (Nasdaq: INCY) today announced a new global collaboration to develop a novel diagnostic panel to support Incyte’s extensive portfolio of investigational therapies for patients with myeloproliferative neoplasms (MPNs), a group of rare blood cancers, including Incyte’s monoclonal antibody INCA033989, targeting mutant calreticulin (mutCALR), which is being developed in myelofi...

WILMINGTON, Del.--(BUSINESS WIRE)--Positive Late-Breaking Data for Incyte’s First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA2025...

BAODING, China--(BUSINESS WIRE)--While new energy vehicles continue to gain momentum worldwide, efficient diesel power remains a compelling choice—especially in challenging off-road environments where torque, range, and reliability are critical. GWM is advancing diesel technology with a focus on refinement, performance, and real-world usability. At the recent GWM Thailand Diesel Day event, the brand demonstrated how modern diesel can deliver a clean, quiet, and highly capable driving experience...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today provided a safety update regarding ELEVIDYS (delandistrogene moxeparvovec-rokl), the only approved gene therapy for patients with Duchenne muscular dystrophy, and steps the Company is taking to strengthen the safety profile in non-ambulatory patients. These steps follow a second reported case of acute liver failure (ALF) resulting in death. The cases of...

TÓQUIO--(BUSINESS WIRE)--A Kao Corporation (TÓQUIO: 4452) publicou o Kao Integrated Report 2025 (Relatório Integrado Kao de 2025) em seu site, oferecendo aos acionistas, investidores e todas as partes interessadas uma visão geral abrangente das iniciativas e da direção estratégica da empresa. Kao Integrated Report 2025 Para alcançar seu Plano de Médio Prazo “K27”, a Kao pretende se tornar uma presença única e indispensável para alguém no mundo e está avançando em sua estratégia Global Sharp Top...

东京--(BUSINESS WIRE)--(美国商业资讯)-- Kao Corporation（TOKYO：4452） 已在官网发布《Kao 2025年综合报告》，向股东、投资者及所有利益相关方全面阐述企业举措与战略方向。 《Kao 2025年综合报告》 为实现中期经营计划“K27”，Kao致力于成为全球不可或缺的独特存在，并且持续推进Global Sharp Top（全球聚焦）战略。2024财年，通过强化投资资本回报率（ROIC）管理和战略性投资布局，Kao成功超额完成目标，构建起更具韧性的业务体系。 本报告详细介绍了Kao在K27计划下取得的进展，重点介绍了敬业的Kao员工通过Global Sharp Top战略与敏捷开发团队模式，正在积极创造新价值，推动产生重大影响力。报告还介绍了Kao依托独特的科技优势，不断努力解决重大挑战，积极应对全球性社会课题，并推动实现所有生命和谐共生的Kirei美好世界。 Kao期待本报告能增进利益相关方的理解，促进深度对话与合作。公司致力于积极采纳不同合作伙伴的反馈意见和见解，不断提高对社会的积极贡献和企业价值。 相关信息 《Kao 2025年可持续...

東京--(BUSINESS WIRE)--(美國商業資訊)-- Kao Corporation (TOKYO:4452)已在其網站發表《Kao 2025年綜合報告》，為股東、投資人及所有利害關係人全面概述公司的措施與策略方向。 《Kao 2025年綜合報告》 為實現其中期計畫「K27」，Kao立志成為對全球消費者不可或缺的獨特存在，並推進其Global Sharp Top策略。2024會計年度，Kao強化投入資本報酬率(ROIC)管理並進行策略投資以建構更強大、更穩健的業務，從而超額完成目標。 本報告深入解析Kao在K27架構下的進展，重點呈現敬業的Kao員工如何透過Global Sharp Top策略與敏捷的Scrum團隊模式，積極創造新價值並推動深遠影響。報告還概述了Kao持續致力於迎接大膽挑戰的努力——利用其獨特科學專長解決全球社會問題，協助實現所有生命和諧共生的Kirei世界。 Kao希望該報告能加深利害關係人的理解，並促進有意義的對話與合作。公司致力於積極納入各方回饋與洞見，持續提升對社會的積極貢獻與企業價值。 相關資訊 《Kao 2025年永續發展報告》 關於Kirei L...